Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same author

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Nature communications·2026
Same author

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.

Nature cancer·2026
Same author

The addition of PARP inhibition to androgen receptor pathway inhibition in metastatic hormone-sensitive prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same author

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

The Lancet. Oncology·2026
Same journal

Temporal trajectories underlying adult neuronal diversity.

Current opinion in genetics & development·2026
Same journal

Transcription regulation of cell fate plasticity - from embryonic development to tissue regeneration.

Current opinion in genetics & development·2026
Same journal

Shared molecular and cellular programs during regeneration of glandular epithelia.

Current opinion in genetics & development·2026
Same journal

Lineage tracing in human cortical development.

Current opinion in genetics & development·2026
Same journal

Cis-regulatory strategies in developmental patterning.

Current opinion in genetics & development·2026
Same journal

GABAergic neuron fate specification and lineage allocation: from development to disorder.

Current opinion in genetics & development·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
05:22

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

Utilizing circulating tumor cells: challenges and pitfalls.

Gerhardt Attard1, Johann S de Bono

  • 1Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK.

Current Opinion in Genetics & Development
|November 30, 2010
PubMed
Summary
This summary is machine-generated.

Circulating tumor cells (CTCs) offer potential for cancer risk assessment and treatment monitoring. Overcoming challenges in CTC detection and analysis is key to expanding their clinical application in early disease and targeted therapies.

More Related Videos

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
05:22

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Circulating tumor cells (CTCs) are detectable in cancer patient blood.
  • Current CTC research primarily focuses on advanced cancer enumeration.
  • CTC evaluation technologies hold promise for broader clinical use.

Purpose of the Study:

  • To review the challenges and potential of circulating tumor cell (CTC) evaluation.
  • To explore the expansion of CTC analysis into early disease detection and treatment monitoring.
  • To discuss the use of CTCs for patient selection in targeted therapies.

Main Methods:

  • Literature review of current CTC detection and analysis technologies.
  • Discussion of challenges in CTC enumeration and molecular profiling.
  • Analysis of the biological differences between CTCs and metastatic tissues.

Main Results:

  • CTCs can be used for risk-stratification and molecular subclassification.
  • Further development could enable CTC use in early-stage disease and treatment response monitoring.
  • CTC-derived signatures may guide targeted therapy selection.

Conclusions:

  • Significant challenges remain in CTC analysis, including absence in some patients, molecular heterogeneity, and ex vivo viability issues.
  • Addressing these challenges is crucial for realizing the full clinical potential of CTCs.
  • Advancements in CTC technology could revolutionize cancer management from early detection to personalized treatment.